Attaya Suvannasankha, MD
Associate Professor of Clinical Medicine
- Address
-
Joseph E. Walther Hall, Room C400
980 W. Walnut St.
Indianapolis , IN 46202 - PubMed:
-
| Year | Degree | Institution |
|---|---|---|
| 2003 | Fellowship | Roswell Park Cancer Institute and State University, Buffalo, NY |
| 1999 | Residency | Albert Einstein Medical Center, Philadelphia, PA |
| 1996 | MD | Chulalongkorn University |
Molecular mechanism of drug resistance in hematologic malignancy
GFI1-Dependent Repression of <i>SGPP1</i> Increases Multiple Myeloma Cell Survival.
Petrusca DN; Mulcrone PL; Macar DA; Bishop RT; Berdyshev E; Suvannasankha A; Anderson JL; Sun Q; Auron PE; Galson DL; Roodman GD; Cancers 2022 Feb 2
Petrusca DN; Mulcrone PL; Macar DA; Bishop RT; Berdyshev E; Suvannasankha A; Anderson JL; Sun Q; Auron PE; Galson DL; Roodman GD; Cancers 2022 Feb 2
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor?+?Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V; Advances in therapy 2021 Sep 24
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V; Advances in therapy 2021 Sep 24
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y; Expert review of hematology 2021 Sep 20
Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y; Expert review of hematology 2021 Sep 20
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD; Cancer 2021 Jul 27
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD; Cancer 2021 Jul 27
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD; The Lancet. Oncology 2019 Dec 16
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD; The Lancet. Oncology 2019 Dec 16
Testicular plasmacytoma misdiagnosed as orchitis.
Schiavo C; Mann SA; Mer J; Suvannasankha A; 2018 Jun 4
Schiavo C; Mann SA; Mer J; Suvannasankha A; 2018 Jun 4
The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Lontos K; Adamik J; Tsagianni A; Galson DL; Chirgwin JM; Suvannasankha A; 2018 Jun 19
Lontos K; Adamik J; Tsagianni A; Galson DL; Chirgwin JM; Suvannasankha A; 2018 Jun 19
Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma.
Wongsaengsak S; Czader M; Suvannasankha A; 2018 Jul 10
Wongsaengsak S; Czader M; Suvannasankha A; 2018 Jul 10
Multiple 'doughnut' granulomas in a liver transplant patient with CMV reactivation.
Dejhansathit S; Miller AM; Suvannasankha A; 2018 Dec 22
Dejhansathit S; Miller AM; Suvannasankha A; 2018 Dec 22
Acute lymphoblastic leukaemia with osteolytic bone lesions: diagnostic dilemma.
Angsubhakorn N; Suvannasankha A; 2018 Aug 11
Angsubhakorn N; Suvannasankha A; 2018 Aug 11
Multifocal myeloid sarcomas: a rare presentation of AML.
Angsubhakorn N; Suvannasankha A; BMJ case reports 2017 Oct 4
Angsubhakorn N; Suvannasankha A; BMJ case reports 2017 Oct 4
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S; Blood 2017 Jun 21
Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S; Blood 2017 Jun 21
Consecutive epigenetically-active agent combinations act in <i>ID1-RUNX3-TET2</i> and <i>HOXA</i> pathways for <i>Flt3ITD+ve</i> AML.
Sayar H; Liu Y; Gao R; Zaid MA; Cripe LD; Weisenbach J; Sargent KJ; Nassiri M; Li L; Konig H; Suvannasankha A; Pan F; Shanmugam R; Goswami C; Kapur R; Xu M; Boswell HS; Oncotarget 2017 Dec 25
Sayar H; Liu Y; Gao R; Zaid MA; Cripe LD; Weisenbach J; Sargent KJ; Nassiri M; Li L; Konig H; Suvannasankha A; Pan F; Shanmugam R; Goswami C; Kapur R; Xu M; Boswell HS; Oncotarget 2017 Dec 25
Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM; Surgery 2015 Jul 21
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM; Surgery 2015 Jul 21
FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.
Suvannasankha A; Tompkins DR; Edwards DF; Petyaykina KV; Crean CD; Fournier PG; Parker JM; Sandusky GE; Ichikawa S; Imel EA; Chirgwin JM; Oncotarget 2015 Aug 14
Suvannasankha A; Tompkins DR; Edwards DF; Petyaykina KV; Crean CD; Fournier PG; Parker JM; Sandusky GE; Ichikawa S; Imel EA; Chirgwin JM; Oncotarget 2015 Aug 14
Regulation of ubiquitin-proteasome system-mediated Tip110 protein degradation by USP15.
Timani KA; Liu Y; Suvannasankha A; He JJ; The international journal of biochemistry & cell biology 2014 Jun 28
Timani KA; Liu Y; Suvannasankha A; He JJ; The international journal of biochemistry & cell biology 2014 Jun 28
Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.
Siclari VA; Mohammad KS; Tompkins DR; Davis H; McKenna CR; Peng X; Wessner LL; Niewolna M; Guise TA; Suvannasankha A; Chirgwin JM; Breast cancer research : BCR 2014 Dec 2
Siclari VA; Mohammad KS; Tompkins DR; Davis H; McKenna CR; Peng X; Wessner LL; Niewolna M; Guise TA; Suvannasankha A; Chirgwin JM; Breast cancer research : BCR 2014 Dec 2
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Suvannasankha A; Chirgwin JM; Breast cancer research : BCR 2014
Suvannasankha A; Chirgwin JM; Breast cancer research : BCR 2014
Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.
Wang H; Cai S; Ernstberger A; Bailey BJ; Wang MZ; Cai W; Goebel WS; Czader MB; Crean C; Suvannasankha A; Shokolenkoc I; Wilson GL; Baluyut AR; Mayo LD; Pollok KE; Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Mar 27
Wang H; Cai S; Ernstberger A; Bailey BJ; Wang MZ; Cai W; Goebel WS; Czader MB; Crean C; Suvannasankha A; Shokolenkoc I; Wilson GL; Baluyut AR; Mayo LD; Pollok KE; Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Mar 27
Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing.
Laínez JM; Orcun S; Pekny JF; Reklaitis GV; Suvannasankha A; Fausel C; Anaissie EJ; Blau GE; Pharmacotherapy 2013 Aug 27
Laínez JM; Orcun S; Pekny JF; Reklaitis GV; Suvannasankha A; Fausel C; Anaissie EJ; Blau GE; Pharmacotherapy 2013 Aug 27
Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study.
Blau GE; Orcun S; Laínez JM; Reklaitis GV; Suvannasankha A; Fausel C; Anaissie EJ; Pharmacotherapy 2013 Apr 3
Blau GE; Orcun S; Laínez JM; Reklaitis GV; Suvannasankha A; Fausel C; Anaissie EJ; Pharmacotherapy 2013 Apr 3
A noncanonical Flt3ITD/NF-?B signaling pathway represses DAPK1 in acute myeloid leukemia.
Shanmugam R; Gade P; Wilson-Weekes A; Sayar H; Suvannasankha A; Goswami C; Li L; Gupta S; Cardoso AA; Al Baghdadi T; Sargent KJ; Cripe LD; Kalvakolanu DV; Boswell HS; Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Nov 17
Shanmugam R; Gade P; Wilson-Weekes A; Sayar H; Suvannasankha A; Goswami C; Li L; Gupta S; Cardoso AA; Al Baghdadi T; Sargent KJ; Cripe LD; Kalvakolanu DV; Boswell HS; Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Nov 17
Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
Abonour R; Kramer G; Suvannasankha A; Benson MD; Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2011 Jun
Abonour R; Kramer G; Suvannasankha A; Benson MD; Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2011 Jun
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS; British journal of haematology 2010 Jun 15
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS; British journal of haematology 2010 Jun 15
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Zhang S; Suvannasankha A; Crean CD; White VL; Chen CS; Farag SS; International journal of cancer. Journal international du cancer 2010 Dec 1
Zhang S; Suvannasankha A; Crean CD; White VL; Chen CS; Farag SS; International journal of cancer. Journal international du cancer 2010 Dec 1
Gastrointestinal plasmacytoma presenting as gastrointestinal bleeding.
Suvannasankha A; Abonour R; Cummings OW; Liangpunsakul S; Clinical lymphoma & myeloma 2008 Oct
Suvannasankha A; Abonour R; Cummings OW; Liangpunsakul S; Clinical lymphoma & myeloma 2008 Oct
Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 15
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Mar 15
Deep vein thrombosis and pulmonary embolism in cirrhosis patients.
Gulley D; Teal E; Suvannasankha A; Chalasani N; Liangpunsakul S; Digestive diseases and sciences 2008 Apr 29
Gulley D; Teal E; Suvannasankha A; Chalasani N; Liangpunsakul S; Digestive diseases and sciences 2008 Apr 29
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R; The oncologist 2007 Jan
Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R; The oncologist 2007 Jan
OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS; Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Aug 15
Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS; Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Aug 15
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
Suvannasankha A; Smith GG; Juliar BE; Abonour R; Clinical lymphoma & myeloma 2006 Sep
Suvannasankha A; Smith GG; Juliar BE; Abonour R; Clinical lymphoma & myeloma 2006 Sep
Hematologic malignancies; multiple myeloma
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.